tetano
Editor, Senior Moderator
Biology (Basel)
. 2021 Jan 13;10(1):E54.
doi: 10.3390/biology10010054.
Cutaneous Manifestations in COVID-19: Report on 31 Cases from Five Countries
Carmen Rodriguez-Cerdeira[SUP] 1 2 3 [/SUP], Brianda I Uribe-Camacho[SUP] 1 4 [/SUP], Lianet Silverio-Carrasco[SUP] 1 5 6 [/SUP], Wennia M?ndez[SUP] 5 7 [/SUP], Ashwini R Mahesh[SUP] 8 [/SUP], Anakaren Tejada[SUP] 5 7 [/SUP], Angelica Beirana[SUP] 9 [/SUP], Erick Martinez-Herrera[SUP] 1 10 [/SUP], Alfonso Alba[SUP] 1 11 [/SUP], Roberto Arenas[SUP] 1 12 [/SUP], Jacek C Szepietowski[SUP] 13 [/SUP]
Affiliations
Abstract
The increasingly frequent cutaneous manifestations of coronavirus disease (COVID-19) remain to pose a problem to clinicians. Herein, we aimed to describe the clinical and pathological findings of skin lesions in patients with COVID-19. The case series, which was based on the International Dermatological Registry circulated to dermatologists worldwide, was conducted across organizations and societies belonging to five different countries. We documented 31 patients with dermatologic manifestations associated with COVID-19, including maculopapular rashes (16.10%), urticarial lesions (26.80%), pseudochilblains (22.60%), petechiae/purpura (6.50%), distal ischaemia and necrosis (6.50%), livedo racemosa (12.90%), and others (9.70%). Twenty-six cases (83.90%) were qRT-PCR-confirmed COVID-19 cases, two (6.50%) were serologically confirmed, while two others (9.7%) were suspected cases owing to previous contact with COVID-19-positive patients. Therefore, our findings indicate that a febrile rash or even a rash in an afebrile state in the early stages of the disease may be the only clinical manifestation of COVID-19. In the future, we recommend close monitoring of all patients with skin lesions not attributable to other causal factors; in the diagnostic perspective, clinicians should aim to confirm if the skin lesions are associated with COVID-19.
Keywords: COVID-19; maculopapular rash; skin lesions.
. 2021 Jan 13;10(1):E54.
doi: 10.3390/biology10010054.
Cutaneous Manifestations in COVID-19: Report on 31 Cases from Five Countries
Carmen Rodriguez-Cerdeira[SUP] 1 2 3 [/SUP], Brianda I Uribe-Camacho[SUP] 1 4 [/SUP], Lianet Silverio-Carrasco[SUP] 1 5 6 [/SUP], Wennia M?ndez[SUP] 5 7 [/SUP], Ashwini R Mahesh[SUP] 8 [/SUP], Anakaren Tejada[SUP] 5 7 [/SUP], Angelica Beirana[SUP] 9 [/SUP], Erick Martinez-Herrera[SUP] 1 10 [/SUP], Alfonso Alba[SUP] 1 11 [/SUP], Roberto Arenas[SUP] 1 12 [/SUP], Jacek C Szepietowski[SUP] 13 [/SUP]
Affiliations
- PMID: 33451000
- DOI: 10.3390/biology10010054
Abstract
The increasingly frequent cutaneous manifestations of coronavirus disease (COVID-19) remain to pose a problem to clinicians. Herein, we aimed to describe the clinical and pathological findings of skin lesions in patients with COVID-19. The case series, which was based on the International Dermatological Registry circulated to dermatologists worldwide, was conducted across organizations and societies belonging to five different countries. We documented 31 patients with dermatologic manifestations associated with COVID-19, including maculopapular rashes (16.10%), urticarial lesions (26.80%), pseudochilblains (22.60%), petechiae/purpura (6.50%), distal ischaemia and necrosis (6.50%), livedo racemosa (12.90%), and others (9.70%). Twenty-six cases (83.90%) were qRT-PCR-confirmed COVID-19 cases, two (6.50%) were serologically confirmed, while two others (9.7%) were suspected cases owing to previous contact with COVID-19-positive patients. Therefore, our findings indicate that a febrile rash or even a rash in an afebrile state in the early stages of the disease may be the only clinical manifestation of COVID-19. In the future, we recommend close monitoring of all patients with skin lesions not attributable to other causal factors; in the diagnostic perspective, clinicians should aim to confirm if the skin lesions are associated with COVID-19.
Keywords: COVID-19; maculopapular rash; skin lesions.